Literature DB >> 29453606

Effect of topiroxostat in patients with diabetic nephropathy and gout or hyperuricemia: fact or fallacy.

Venu Gopal Jonnalagadda1, Harish Prabhanna Char2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29453606     DOI: 10.1007/s10157-018-1540-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  1 in total

1.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.